Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

NCT00156377

Cross Infection Staphylococcal Infections

COMPLETED PHASE4

Impact of Mupirocin Decolonization on the Nasal Microbiome

NCT02045329

Nasal Colonization With Staph Aureus

TERMINATED

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

NCT02284555

Staphylococcal Infection

COMPLETED PHASE4

A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections

NCT01049438

Methicillin Resistant Staphylococcus Aureus Skin Infections

COMPLETED NA

Inflammation, Intracellular Invasion and Colonization of the Nasal Mucosa by Staphylococcus Aureus

NCT04469348

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasal Carriers of Staphylococcus Aureus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)

2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to give informed consent
* Must have consented prior to registration for the study

Exclusion Criteria

* active infection
* concurrent treatment with antibiotics, topical or systemic
* S. aureus decolonization attempt in prior six months
* history of HIV
* chemotherapy or systemic immunosuppressive therapy
* history of neomycin allergy or sensitivity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes